Hepatobiliary Cancers: Translational Advances and Molecular Medicine PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Hepatobiliary Cancers: Translational Advances and Molecular Medicine PDF full book. Access full book title Hepatobiliary Cancers: Translational Advances and Molecular Medicine by . Download full books in PDF and EPUB format.
Author:
Publisher: Academic Press
ISBN: 0323983936
Category : Science
Languages : en
Pages : 468
Get Book Here
Book Description
Hepatobiliary cancer refers to primary malignant tumors originating in cells of the liver, bile ducts, and gallbladder. Globally, primary liver cancer, which includes hepatocellular carcinoma (~75 % of all cases) and intrahepatic biliary cancer or cholangiocarcinoma (~10-15 % 0f all cases) is the 6th most commonly diagnosed cancer and 3rd leading cause of cancer deaths worldwide. The vast majority of these highly malignant cancers are diagnosed at an advanced stage where treatment options are limited and patient survival outcomes are poor. The biological and therapeutic challenges posed by hepatobililiary cancers such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are daunting, emphasizing a critical need to review and assess current and evolving basic, translational, and clinical research focused on addressing the critical obstacles that continue to limit progress towards achieving significant improvements in HCC and CCA clinical management and patient survival outcomes. Towards this goal, this special edition of Advances in Cancer Research is focused on providing a comprehensive, timely and authoritative reviews covering such topics of significant scientific and clinical relevance, including hepatobiliary cancer risk mechanisms and risk-predictive molecular biomarkers; causes and functional intricacies of inter- and intratumor heterogeneity; novel insights into the role of tumor microenvironment and key signaling pathways in promoting hepatobiliary cancer progression, therapeutic resistance and immunosuppression; emerging biomarkers of HCC and CCA prognosis; advances in molecular genomics for personalizing tumor classification and targeted therapies; innovative preclinical cell culture modeling for hepatobiliary cancer drug discovery; and current and emerging trends in hepatobiliary cancer molecular therapeutic targeting and immunotherapies. Up-to date review of hepatobiliary cancers molecular genetics, novel predictive molecular biomarkers, and distinct mechanisms of inter-and intratumor heterogeneity Novel insights into the role of tumor microenvironment as a promoter of hepatobiliary cancer progression and therapeutic resistance, as well as an emerging therapeutic target Current and emerging approaches and strategies for advancing personalized molecular therapeutic targeting and immunotherapy of hepatobiliary cancers
Author:
Publisher: Academic Press
ISBN: 0323983936
Category : Science
Languages : en
Pages : 468
Get Book Here
Book Description
Hepatobiliary cancer refers to primary malignant tumors originating in cells of the liver, bile ducts, and gallbladder. Globally, primary liver cancer, which includes hepatocellular carcinoma (~75 % of all cases) and intrahepatic biliary cancer or cholangiocarcinoma (~10-15 % 0f all cases) is the 6th most commonly diagnosed cancer and 3rd leading cause of cancer deaths worldwide. The vast majority of these highly malignant cancers are diagnosed at an advanced stage where treatment options are limited and patient survival outcomes are poor. The biological and therapeutic challenges posed by hepatobililiary cancers such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are daunting, emphasizing a critical need to review and assess current and evolving basic, translational, and clinical research focused on addressing the critical obstacles that continue to limit progress towards achieving significant improvements in HCC and CCA clinical management and patient survival outcomes. Towards this goal, this special edition of Advances in Cancer Research is focused on providing a comprehensive, timely and authoritative reviews covering such topics of significant scientific and clinical relevance, including hepatobiliary cancer risk mechanisms and risk-predictive molecular biomarkers; causes and functional intricacies of inter- and intratumor heterogeneity; novel insights into the role of tumor microenvironment and key signaling pathways in promoting hepatobiliary cancer progression, therapeutic resistance and immunosuppression; emerging biomarkers of HCC and CCA prognosis; advances in molecular genomics for personalizing tumor classification and targeted therapies; innovative preclinical cell culture modeling for hepatobiliary cancer drug discovery; and current and emerging trends in hepatobiliary cancer molecular therapeutic targeting and immunotherapies. Up-to date review of hepatobiliary cancers molecular genetics, novel predictive molecular biomarkers, and distinct mechanisms of inter-and intratumor heterogeneity Novel insights into the role of tumor microenvironment as a promoter of hepatobiliary cancer progression and therapeutic resistance, as well as an emerging therapeutic target Current and emerging approaches and strategies for advancing personalized molecular therapeutic targeting and immunotherapy of hepatobiliary cancers
Author: Yujin Hoshida
Publisher: Springer
ISBN: 3030215407
Category : Medical
Languages : en
Pages : 366
Get Book Here
Book Description
This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields. By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC.
Author: Yunfei Xu
Publisher: Frontiers Media SA
ISBN: 2832547958
Category : Science
Languages : en
Pages : 295
Get Book Here
Book Description
Download the ebooks for this Research Topic: Volume I.A: ¦PDF¦ ¦EPUB Volume I.B: ¦PDF¦ ¦ EPUB Hepatobiliary tumor, mainly including hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer, is a group of highly aggressive malignancies. Hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer have different biological characters, histopathological traits, and treatment strategies, but have similar clinical features such as silent early symptom and extremely poor prognosis. The diagnostic, predictive or prognostic tumor biomarkers of hepatobiliary cancers are in unmet need. In contrast to the poor outcome, the treatment options to hepatobiliary cancers are very limited. It is still controversial about the effects of chemotherapy and radiotherapy of hepatobiliary cancer. FDA-approved targeted drugs are only Sorafenib and Lenvatinib for hepatocellular carcinoma, and Pemigatinib for cholangiocarcinoma. Unfortunately, these drugs are only effective for 5%-30% patients. Therefore, more attention should be called upon on investigating effective biomarkers and drug targets, stratifying high-risk patients, guiding precise treatments, and developing therapeutic strategies for hepatobiliary cancers. This Research Topic aims at discussing the current knowledge and proceedings of diagnostic, predictive and prognostic tumor biomarkers in hepatobiliary cancer, and presenting the recent advances on new drug targets and potential targeted therapies of hepatobiliary cancer. We welcome submissions of Review, Mini-Review, Clinical Trial and Original Research articles covering, but not limited to, the following topics: 1. new diagnostic/prognostic factors, biomarkers and/or risk factors in hepatobiliary tumors 2. new drug targets, and oncogenic or tumor suppressive molecular mechanism of the novel targets 3. new intervention or targeted therapy in hepatobiliary tumors 4. new findings of bioinformatics or high-throughput methods such as mass spectrometry and genome-wide association studies or which may help screen the potential biomarkers of hepatobiliary tumors 5. clinical studies such as cohort study or RCT to identify new risks or treatment therapies in hepatobiliary tumors 6. basic, pharmacological, preclinical or clinical study of potential drugs targeting hepatobiliary tumors Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Author: Yuman Fong
Publisher: Pmph-USA, Limited
ISBN: 9781607952220
Category : Liver
Languages : en
Pages : 400
Get Book Here
Book Description
Hepatobiliary cancers have yielded to technological advances in imaging and therapy so that diagnosis of these cancers no longer carries with it a prognosis of certain death.The international group of experts who have contributed the chapters to this volume from world-class cancer center provide a summary of the current state of the art for diagnosis and treatment on hepatobiliary cancers. The institutions represented include Memorial Sloan Kettering Cancer Center, The Johns Hopkins Hospital, the Mayo Clinic, Brown University, Columbia University, Northwestern University, UC San Francisco, Sanjay Gandhi Institute, Saint Barnabas Medical Center, the University of Heidelberg, the University of Wisconsin, the University of Hong Kong, Fudan University/Shanghai Cancer Center, Florida International University, the Institute of Cancer Studies, University Hospital, Birmingham (UK), and the University of Tokyo.The book looks at these cancers by type - biliary and liver tumors - and in terms of diagnostic techniques and therapies: surgical, ablative, systemic and regional chemotherapies, biologic, and complementary.This volume is essential reading for anyone engaged in learning about and treating hepatobiliary cancers"
Author: Tim F. Greten
Publisher: Springer
ISBN: 9783319879116
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
Author: Paul H. Sugarbaker
Publisher:
ISBN: 9781461526056
Category :
Languages : en
Pages : 348
Get Book Here
Book Description
Author: Mauro Monteiro Correia
Publisher: Springer Nature
ISBN: 3030254860
Category : Medical
Languages : en
Pages : 597
Get Book Here
Book Description
Colorectal cancer is the third most commonly diagnosed condition in oncology, affecting around 1.23 million individuals per year, according to recent statistics. Of these patients, about 50% will develop liver metastases and approximately 20% will present a stage IV disease at diagnosis. These statistics make colorectal liver metastases (CLM) an issue of major importance in current oncology. The area of CLM is subject to great and continuous advances, as its pathophysiologic mechanisms are better understood and more therapeutic and surgical options are developed. Consequently, all professionals involved with the diagnosis, treatment and follow up of CLM should be kept up to date with the latest advances on the field, to provide high standard medical care to their patients. This book is designed to present the state-of-the-art in CLM management and, in doing so, to review the current evidence on CLM, discussing all important topics in the field. Coverage is broad and comprehensive, encompassing introductory topics (history, definitions, epidemiology, etc.), basic science subjects (molecular biology, genetics, dissemination process, etc.) and practical clinical topics (tumor behavior, diagnosis, drug therapy, radiation therapy, surgery, ablation, multidisciplinary teams, etc.). Although comprehensive on the coverage and selection of topics, each chapter is concise and objective, dissecting topics in a practical and direct format. Evidences and recommendations are included. Chapters display a brief introduction of the common knowledge, go straight to the detailed revision of the most recent years of the literature, and end with practical closing observations. This book is a tool for professionals (general and cancer surgeons, HPB surgeons, clinical oncologists, gastroenterologists and medical residents) and interns who search for a qualified and reader friendly revision on topics concerning Colorectal Cancer Liver Metastases.
Author: James H. Tabibian
Publisher: Springer Nature
ISBN: 3030709361
Category : Medical
Languages : en
Pages : 589
Get Book Here
Book Description
This book provides a comprehensive, state-of-the-art overview of cholangiocarcinoma (CCA). The text is structured to effectively present a broad yet concise overview of bile duct cancer, its relevant definitions, classification schemata, clinical management tenets, translational (including molecular and cellular) facets, and future directions. The book features numerous high-yield illustrations and is authored by an eclectic range of renowned experts in various areas of CCA, reflecting the multidisciplinary nature of the field. Filling a critical gap in the field, Diagnosis and Management of Cholangiocarcinoma: A Multidisciplinary Approach is a valuable resource for clinicians and practitioners who treat patients with bile duct cancer.
Author: Harvey Pass
Publisher: Elsevier Health Sciences
ISBN: 0323527841
Category : Medical
Languages : en
Pages : 904
Get Book Here
Book Description
Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today's best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies. - Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy. - Provides authoritative guidance from the IASLC – the only global organization dedicated to the study of lung cancer. - Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer. - Features a new full-color design throughout, as well as updated diagnostic algorithms. - Expert ConsultTM eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, Q&As, and references from the book on a variety of devices.
Author: Marcello Maresca
Publisher: John Wiley & Sons
ISBN: 1119671396
Category : Science
Languages : en
Pages : 355
Get Book Here
Book Description
GENOME EDITING IN DRUG DISCOVERY A practical guide for researchers and professionals applying genome editing techniques to drug discovery In Genome Editing in Drug Discovery, a team of distinguished biologists delivers a comprehensive exploration of genome editing in the drug discovery process, with coverage of the technology’s history, current issues and techniques, and future perspectives and research directions. The book discusses techniques for disease modeling, target identification with CRISPR, safety studies, therapeutic editing, and intellectual property issues. The safety and efficacy of drugs and new target discovery, as well as next-generation therapeutics are also presented. Offering practical suggestions for practitioners and academicians involved in drug discovery, Genome Editing in Drug Discovery is a fulsome treatment of a technology that has become part of nearly every early step in the drug discovery pipeline. Selected contributions also include: A thorough introduction to the applications of CRISPRi and CRISPRa in drug discovery Comprehensive explorations of genome-editing applications in stem cell engineering and regenerative medicine Practical discussions of the safety aspects of genome editing with respect to immunogenicity and the specificity of CRISPR-Cas9 gene editing In-depth examinations of critical socio-economic and bioethical challenges in the CRISPR-Cas9 patent landscape Perfect for academic researchers and professionals in the biotech and pharmaceutical industries, Genome Editing in Drug Discovery will also earn a place in the libraries of medicinal chemists, biochemists, and molecular biologists.
